Next Article in Journal
Eco-Friendly Functionalization of Ynals with Thiols under Mild Conditions
Previous Article in Journal
Systematic Analysis of the BrHAT Gene Family and Physiological Characteristics of Brassica rapa L. Treated with Histone Acetylase and Deacetylase Inhibitors under Low Temperature
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
This is an early access version, the complete PDF, HTML, and XML versions will be available soon.
Review

Development and Prospects of Furin Inhibitors for Therapeutic Applications

by
Alexandre V. Ivachtchenko
*,
Alexander V. Khvat
and
Dmitrii O. Shkil
ChemDiv Inc., San Diego, CA 92130, USA
*
Author to whom correspondence should be addressed.
Int. J. Mol. Sci. 2024, 25(17), 9199; https://doi.org/10.3390/ijms25179199 (registering DOI)
Submission received: 22 July 2024 / Revised: 17 August 2024 / Accepted: 22 August 2024 / Published: 24 August 2024
(This article belongs to the Section Biochemistry)

Abstract

Furin, a serine protease enzyme located in the Golgi apparatus of animal cells, plays a crucial role in cleaving precursor proteins into their mature, active forms. It is ubiquitously expressed across various tissues, including the brain, lungs, gastrointestinal tract, liver, pancreas, and reproductive organs. Since its discovery in 1990, furin has been recognized as a significant therapeutic target, leading to the active development of furin inhibitors for potential use in antiviral, antibacterial, anticancer, and other therapeutic applications. This review provides a comprehensive overview of the progress in the development and characterization of furin inhibitors, encompassing peptides, linear and macrocyclic peptidomimetics, and non-peptide compounds, highlighting their potential in the treatment of both infectious and non-infectious diseases.
Keywords: furin; PACE; PCSK3; PC1; PC3; PC1/3; proprotein convertase (PC); pan-protease inhibitor; serine protease inhibitor; viral proteins HIV; influenza; SARS-CoV-2; COVID-19; bacterial toxins; cancers furin; PACE; PCSK3; PC1; PC3; PC1/3; proprotein convertase (PC); pan-protease inhibitor; serine protease inhibitor; viral proteins HIV; influenza; SARS-CoV-2; COVID-19; bacterial toxins; cancers

Share and Cite

MDPI and ACS Style

Ivachtchenko, A.V.; Khvat, A.V.; Shkil, D.O. Development and Prospects of Furin Inhibitors for Therapeutic Applications. Int. J. Mol. Sci. 2024, 25, 9199. https://doi.org/10.3390/ijms25179199

AMA Style

Ivachtchenko AV, Khvat AV, Shkil DO. Development and Prospects of Furin Inhibitors for Therapeutic Applications. International Journal of Molecular Sciences. 2024; 25(17):9199. https://doi.org/10.3390/ijms25179199

Chicago/Turabian Style

Ivachtchenko, Alexandre V., Alexander V. Khvat, and Dmitrii O. Shkil. 2024. "Development and Prospects of Furin Inhibitors for Therapeutic Applications" International Journal of Molecular Sciences 25, no. 17: 9199. https://doi.org/10.3390/ijms25179199

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop